Abstract: The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patie

Abstract: The invention relates to a method for detecting, by means of flow cytometry, the presence of normal plasma cells and tumoral plasma cells in a sample of cells from a patient.

Abstract: The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will no

Abstract: The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patie

Abstract: The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will no

Abstract: The present invention relates to a method of testing whether a patient suffering of multiple myeloma will respond or not to a DNA methyltransferase inhibitor (DNMTi) comprising: i. determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii. comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii.

Abstract: The present invention provides methods of treating a subject suffering from multiple myeloma comprising administering to the subject an effect amount of a compound according to Formula I:

Abstract: A golf ball has an axis of rotation and an equator substantially perpendicular to the axis of rotation. A pattern is disposed substantially about the equator of the golf ball at the equator. The pattern has a first color and the golf ball has a second color which is different than the first color so that when the golf ball rotates so that the equator is substantially orthogonal to the axis of rotation the pattern exhibits one color, but if the ball rolls so that the equator rolls not substantially orthogonal to the axis of rotation, it exhibits a second color. In a preferred embodiment, the color of the golf ball is white and the different colors are the true color of the pattern and shades of that color. Furthermore, in a preferred embodiment, the pattern is asymmetrical but repeating and includes first regions of pattern and second regions of pattern. The first regions of pattern are disposed between successive second regions of pattern.

Abstract: The present invention relates to the use of at least one inhibitor of heparin-binding (HB) epidermal growth factor (EGF), or at least one inhibitor of HB-EGF receptors, or ErbB receptors, or at least one inhibitor of associated transduction pathways for the preparation of drugs useful for inducing the apoptosis and/or inhibiting the proliferation of IL-6-dependent plasmocytic tumor cells.

Abstract: The invention relates to a cell composition containing macrophages, presenting anti-infectious and hematopoietic properties. More particularly, the invention relates to a cell composition containing macrophages, myeloid cells and progenitors; said cell compositions are useful for the restoration of hematopoiesis in an aplasic patient and/or the protection of patients against infectious diseases or against residual tumors.

Abstract: A therapeutic kit which includes at least three unlinked monoclonal antibodies for neutralizing a short life IL-6 cytokine and a method for preparing said kit.

Abstract: A process of isolating beta-lipoproteins from blood serum in about 99% purity comprising precipitating beta-lipoproteins from blood serum substantially free of chylomicrons with polyanethole sulfonate and a divalent cation, forming a solution of the beta-lipoproteins and reprecipitating them with the divalent cation, again forming a solution of said beta-lipoproteins and passing them through a DEAE cellulose column. The beta-lipoproteins purified by the method are particularly suited as a calibration standard for use in assays of the beta-lipoprotein content of blood serum.

Abstract: An envelope for containing photographic prints and negatives in separate pockets comprising substantially rectangular front and back panels interconnected along three edges thereof forming a first pocket particularly adapted for containing photographic prints, and having an insert opening between the remaining edges of the panels. A center flap is connected to the remaining edge of the back panel along a fold line, and overlies a portion of the back panel. A patch member has a lower edge and at least one side edge thereof attached to the center flap forming a second pocket particularly adapted for containing photographic negatives, and having an insert opening along the two remaining edges of the patch. A closure flap is connected to the remaining edge of the front panel along a fold line and overlies the patch member when in a closed position.

Abstract: A snell for connecting a fishhook to a line or leader. The snell, a strand of nylon or like material, is formed with a hook connector at one end and a line connector or eye at the other end as a unitary structure. The hook connector provides a socket to receive and hold the shank end of a hook. The line connector is formed with a passageway commencing at its extended end and exiting from the side of the connector. This passageway receives the end of a line which is threaded through the passageway, knotted and secured thereinto. The mode of manufacture of this snell is to form the same by molding the strand and connectors as a unit. The strand may be subsequently drawn to increase its strength and to reduce its diameter.